Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined array key "thumbnail" in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 25
StackHealth / Merck reorganizes, creating dedicated oncology business unit

Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears

oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]

AI Summary: Merck reorganized its Human Health structure to form a separate oncology business unit, positioning the company to defend and optimize its cancer franchise ahead of Keytruda patent pressures and to sharpen focus across therapeutic areas as part of a broader commercial realignment.

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance

Merck KGaA drops two cancer trials on assets from SpringWorks deal

2 months / endpoints / Reynald Castaneda

No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC

2 months / esmo

Cancer Research UK partners with the Royal College of Surgeons of England to help people with rectal cancer avoid unnecessary surgery

2 months / cancerresearchuk / Krishna Sharma

A domain-adaptive deep contrastive network for magnetic resonance imaging-driven bladder cancer classification

2 months / nature

Multicenter ex vivo evaluation of an α-mannosidase–targeted fluorescent probe for intraoperative margin assessment in breast cancer

2 months / nature

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123

2 months / nature

Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima

3 months / endpoints / Nicole DeFeudis

Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears

3 months / oncodaily

Merck reorganizes; Blackstone to fund trials for J&J drug

3 months / endpoints / ENDPOINTS

Back to Top / Saturday, February 28, 2026, 3:22 am / permalink 19937 / 9 stories in 3 months /


Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61


Related Stories


Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Novartis to build $23B radioligand therapy manufacturing site in Texas / 3 months

Servier to acquire Day One Biopharma for $2.5B / 2 months

Belzutifan combinations highlighted at ASCO GU improve RCC outcomes / 2 months

Rezatapopt shows proof-of-concept reactivating mutant p53 in patients / 2 months

Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in MIBC / 3 months

TTLC 2026 highlights advanced NSCLC symposia and emerging data / 3 months

Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 16 days

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Pricing, Supply Chain, Pediatric Oncology, Infant Health and look for the RSS link.


↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.